Wang Minmin, Winneroski Leonard L, Ardecky Robert J, Babine Robert E, Brooks Dawn A, Etgen Garret J, Hutchison Darrell R, Kauffman Raymond F, Kunkel Aaron, Mais Dale E, Montrose-Rafizadeh Chahrzad, Ogilvie Kathleen M, Oldham Brian A, Peters Mary K, Rito Christopher J, Rungta Deepa K, Tripp Allie E, Wilson Sarah B, Xu Yanping, Zink Richard W, McCarthy James R
Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, IN 46285, USA.
Bioorg Med Chem Lett. 2004 Dec 20;14(24):6113-6. doi: 10.1016/j.bmcl.2004.09.031.
To understand the species selectivity in a series of alpha-methyl-alpha-phenoxy carboxylic acid PPARalpha/gamma dual agonists (1-11), structure-based molecular modeling was carried out in the ligand binding pockets of both human and mouse PPARalpha. This study suggested that interaction of both 4-phenoxy and phenyloxazole substituents of these ligands with F272 and M279 in mouse PPARalpha leads to the species-specific divergence in ligand binding. Insights obtained in the molecular modeling studies of these key interactions resulted in the ability to convert a human-selective PPARalpha agonist to a human and mouse dual agonist within the same platform.
为了解一系列α-甲基-α-苯氧基羧酸PPARα/γ双重激动剂(1-11)的物种选择性,在人源和小鼠源PPARα的配体结合口袋中进行了基于结构的分子建模。该研究表明,这些配体的4-苯氧基和苯基恶唑取代基与小鼠PPARα中的F272和M279相互作用,导致配体结合出现物种特异性差异。在这些关键相互作用的分子建模研究中获得的见解,使得在同一平台内能够将人源选择性PPARα激动剂转化为人源和小鼠源双重激动剂。